[-] Show simple item record

dc.contributor.authorSauereisen, Sandraeng
dc.contributor.authorCastelli, Gregoryeng
dc.contributor.otherFamily Physicians Inquiries Networkeng
dc.date.issued2020eng
dc.descriptionReview of: Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440-453.eng
dc.description.abstractA better approach to preventing active TB? Nine months of isoniazid prevents active TB in those with latent disease. But is there a shorter, less toxic option? PRACTICE CHANGER: Use 4 months of rifampin instead of 9 months of isoniazid to treat adults with latent tuberculosis; rifampin is associated with fewer adverse events and higher completion rates. STRENGTH RECOMMENDATION: B: Based on a randomized controlled trial and a previous Cochrane review.eng
dc.description.statementofresponsibilitySandra Sauereisen, MD, MPH; Gregory Castelli, PharmD, BCPS, BC-ADM UPMC; St. Margaret Family Medicine Residency, Pittsburgh, PAeng
dc.identifier.urihttps://hdl.handle.net/10355/74641
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionPriority Updates to Research Literature (PURLs) (2020)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 69, no. 01 (January 2020): 37-38.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subject.otherTuberculosiseng
dc.subject.otherIsoniazideng
dc.subject.otherRifampineng
dc.subject.otherAdultseng
dc.titleA better approach to preventing active TB?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record